Startups, Venture Capital

Medicxi bankrolls the launch of a pair of biotech twins focused on orexins for narcolepsy and more

The venture investors at Medicxi are funding a pair of biotech spinouts from UK-based Sosei Heptares, which has been fine tuning its expertise in G protein-coupled receptors for a number of years now.

Francesco De Rubertis

Medicxi is offering €40 million to kickstart two new companies — the twins Orexia and Inexia, which will target Orexin OX1 and OX2 for neurological diseases. The Heptares subsidiary will put its researchers to work on the two projects, identifying narcolepsy as one key disease on the menu.

Orexins are well known targets in the biotech world. These neuropeptides are involved in the regulation of sleep, wakefulness and appetite.

Malcolm Weir

Medicxi partner Francesco De Rubertis will sit on the board to watch over the firm’s investment. Both of these groups have deep roots in the UK, with Sosei looking to build up the Heptares operation under Malcolm Weir.

The VC’s cash should be enough to get through proof-of-concept studies, fitting neatly in Medicxi’s asset-centric focus, which often focuses the money on early-stage research programs stripped of as much overhead as they can.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->